Monopar Therapeutics (MNPR) News Today $40.25 -0.72 (-1.76%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$40.58 +0.33 (+0.81%) As of 02/21/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Brookline Capital Management Forecasts MNPR Q1 EarningsFebruary 12, 2025 | americanbankingnews.comQ1 EPS Forecast for Monopar Therapeutics Raised by AnalystMonopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Analysts at Brookline Capital Management increased their Q1 2025 earnings per share estimates for Monopar Therapeutics in a research note issued to investors on Wednesday, February 5th. Brookline Capital Management analyst K. Dolliver now anFebruary 10, 2025 | marketbeat.comWhy Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025February 3, 2025 | msn.comWhat is HC Wainwright's Forecast for MNPR FY2026 Earnings?Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - HC Wainwright lifted their FY2026 EPS estimates for Monopar Therapeutics in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of $0.70 for the yeJanuary 24, 2025 | marketbeat.comRosalind Franklin University's Helix 51 Incubator Welcomes Monopar TherapeuticsJanuary 23, 2025 | prnewswire.comFY2029 Earnings Estimate for MNPR Issued By HC WainwrightMonopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee anticipatesJanuary 23, 2025 | marketbeat.comMonopar Therapeutics price target raised to $40 from $22 at H.C. WainwrightJanuary 23, 2025 | finance.yahoo.comMonopar Therapeutics Gains ‘Buy’ Rating Amid Promising Licensing Deal with AstraZeneca and Strong Growth ProspectsJanuary 22, 2025 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Nektar Therapeutics (NKTR)January 22, 2025 | markets.businessinsider.comHC Wainwright Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) StockHC Wainwright boosted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday.January 22, 2025 | marketbeat.comMonopar Therapeutics files to sell 882,761 shares of common stock for holdersJanuary 16, 2025 | markets.businessinsider.comPiper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight RecommendationJanuary 10, 2025 | msn.comMonopar Therapeutics initiated with an Overweight at Piper SandlerJanuary 10, 2025 | markets.businessinsider.comMonopar Therapeutics: Strategic Advancements and Promising Potential Drive Buy RatingJanuary 10, 2025 | markets.businessinsider.comPiper Sandler Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR)Piper Sandler initiated coverage on Monopar Therapeutics in a research note on Friday. They set an "overweight" rating and a $72.00 target price for the company.January 10, 2025 | marketbeat.comBrookline Capital Management Weighs in on MNPR Q1 EarningsMonopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for Monopar Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst K. Dolliver expects that the company will earnJanuary 9, 2025 | marketbeat.comMonopar: Radiopharmaceutical Company With 2 Radioisotope Development PathwaysDecember 23, 2024 | seekingalpha.comMonopar Therapeutics prices 798,655 shares at $23.79 in registered offeringDecember 21, 2024 | markets.businessinsider.comMonopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded WarrantsDecember 20, 2024 | globenewswire.comHere's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price StrengthDecember 18, 2024 | msn.comMonopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-LuDecember 5, 2024 | globenewswire.comMonopar to Present at the 36th Annual Piper Sandler Healthcare ConferenceDecember 3, 2024 | markets.businessinsider.comMonopar to Present at the 36th Annual Piper Sandler Healthcare ConferenceDecember 3, 2024 | globenewswire.com3 Momentum Stocks Soaring Into 2025 and Beyond (MNPR)Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.December 3, 2024 | marketbeat.comMonopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In FocusNovember 25, 2024 | seekingalpha.comJones Trading raises Monopar Therapeutics target to $37November 21, 2024 | uk.investing.comMonopar Therapeutics Gains Buy Rating Following Strategic Agreement and Promising Phase III Results for Wilson’s Disease TreatmentNovember 20, 2024 | markets.businessinsider.comMonopar Therapeutics price target raised to $37 from $9 at JonesResearchNovember 20, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for MNPR FY2024 Earnings?Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright increased their FY2024 earnings estimates for Monopar Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the company will earn ($1November 14, 2024 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Given New $22.00 Price Target at HC WainwrightHC Wainwright boosted their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the stock a "buy" rating in a report on Monday.November 11, 2024 | marketbeat.comTransformative Licensing Acquisition Drives Buy Rating for Monopar TherapeuticsNovember 11, 2024 | markets.businessinsider.comMonopar Therapeutics price target raised to $22 from $6 at H.C. WainwrightNovember 11, 2024 | markets.businessinsider.comMonopar Therapeutics Inc.: Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | finanznachrichten.deMonopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | markets.businessinsider.comMonopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) CFO Acquires $25,187.50 in StockOctober 31, 2024 | insidertrades.comMonopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common StockOctober 30, 2024 | globenewswire.comMonopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockOctober 28, 2024 | globenewswire.comMonopar Therapeutics Inc. Announces Proposed Public Offering of Common StockOctober 28, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short InterestMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 49,900 shares, a drop of 55.6% from the September 30th total of 112,400 shares. Currently, 2.8% of the company's stock are short sold. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 0.0 days.October 27, 2024 | marketbeat.comIndividual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last weekOctober 26, 2024 | finance.yahoo.comMarketBeat Week in Review – 10/21- 10/25 (MNPR)Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatilityOctober 26, 2024 | marketbeat.comWhat's Going On With Monopar Therapeutics Shares Friday?October 26, 2024 | msn.comMonopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?October 25, 2024 | marketbeat.comMonopar Therapeutics Skyrockets 400% on Licensing DealMonopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.October 25, 2024 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Sets New 52-Week High - Should You Buy?Monopar Therapeutics (NASDAQ:MNPR) Reaches New 1-Year High - Here's WhyOctober 24, 2024 | marketbeat.comMonopar Shares Rise on AstraZeneca Licensing DealOctober 24, 2024 | marketwatch.comMonopar Shares Surge on AstraZeneca Licensing Deal -- UpdateOctober 24, 2024 | marketwatch.comMonopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug CandidateOctober 24, 2024 | markets.businessinsider.comMonopar Therapeutics Unveils Promising Radiopharmaceutical DataOctober 22, 2024 | markets.businessinsider.com Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address MNPR Media Mentions By Week MNPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼0.000.60▲Average Medical News Sentiment MNPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼02▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Phibro Animal Health News Zymeworks News AbCellera Biologics News Replimune Group News Collegium Pharmaceutical News Rocket Pharmaceuticals News Evolus News Pharvaris News ArriVent BioPharma News Cogent Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts